Chronic valproate normalizes behavior in mice overexpressing calcineurin

European Journal of Pharmacology

Volumn 580, Issue 1-2, 2008, Pages 153-160

  Herzog, Claire J ^a   Miot, Stéphanie ^a   Mansuy, Isabelle M ^b   Giros, Bruno ^a   Tzavara, Eleni T ^a  

^a INSERM   (France)

^b University of Zurich Brain Research Institute   (Switzerland)

Author keywords

Affective disorders; Behavioral reactivity; Calcineurin; Cocaine; Mood stabilizer; Valproate

Indexed keywords

CALCINEURIN; COCAINE; MOOD STABILIZER; PSYCHOSTIMULANT AGENT; VALPROIC ACID;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; BEHAVIOR CHANGE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; LOCOMOTION; MAZE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; TRANSGENIC ANIMAL;

ANIMALS; ANTIMANIC AGENTS; BEHAVIOR, ANIMAL; CALCINEURIN; COCAINE; DISEASE MODELS, ANIMAL; GENE EXPRESSION; MAZE LEARNING; MICE; MICE, TRANSGENIC; MOOD DISORDERS; MOTOR ACTIVITY; PHOSPHORYLATION; VALPROIC ACID;

EID: 37649025517     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.10.050     Document Type: Article

References (43)

1. Albert K.A., Hemmings Jr. H.C., Adamo A.I., Potkin S.G., Akbarian S., Sandman C.A., Cotman C.W., Bunney Jr. W.E., and Greengard P. Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia. Arch. Gen. Psychiatry 59 (2002) 705-712
2. Angelucci F., Brene S., and Mathe A.A. BDNF in schizophrenia, depression and corresponding animal models. Mol. Psychiatry 10 (2005) 345-352
3. Arban R., Maraia G., Brackenborough K., Winyard L., Wilson A., Gerrard P., and Large C. Evaluation of the effects of lamotrigine, valproate and carbamazepine in a rodent model of mania. Behav. Brain Res. 158 (2005) 123-132
4. Bhalla U.S., Ram P.T., and Iyengar R. MAP kinase phosphatase as a locus of flexibility in a mitogen-activated protein kinase signaling network. Science 297 (2002) 1018-1023
5. Chan G.C., Tonegawa S., and Storm D.R. Hippocampal neurons express a calcineurin-activated adenylyl cyclase. J. Neurosci. 25 (2005) 9913-9918
6. Charney D.S., and Manji H.K. Life stress, genes, and depression: multiple pathways lead to increased risk and new opportunities for intervention. Sci. STKE 2004 225 (2004) re5
7. Craddock N., O'Donovan M.C., and Owen M.J. Genes for schizophrenia and bipolar disorder? Implications for psychiatric nosology. Schizophr. Bull. 32 (2006) 9-16
8. Crozatier C., Farley S., Mansuy I.M., Dumas S., Giros B., and Tzavara E.T. Calcineurin (protein phosphatase 2B) is involved in the mechanisms of action of antidepressants. Neuroscience 144 (2007) 1470-1476
9. Du J., Gray N.A., Falke C.A., Chen W., Yuan P., Szabo S.T., Einat H., and Manji H.K. Modulation of synaptic plasticity by antimanic agents: the role of AMPA glutamate receptor subunit 1 synaptic expression. J. Neurosci. 24 (2004) 6578-6589
10. Ferguson G.D., Herschman H.R., and Storm D.R. Reduced anxiety and depression-like behavior in synaptotagmin IV (-/-) mice. Neuropharmacology 47 (2004) 604-611
11. Gerber D.J., Hall D., Miyakawa T., Demars S., Gogos J.A., Karayiorgou M., and Tonegawa S. Evidence for association of schizophrenia with genetic variation in the 8p21.3 gene, PPP3CC, encoding the calcineurin gamma subunit. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 8993-8998
12. Gerdjikov T.V., and Beninger R.J. Differential effects of calcineurin inhibition and protein kinase A activation on nucleus accumbens amphetamine-produced conditioned place preference in rats. Eur. J. Neurosci. 22 (2005) 697-705
13. Gessa G.L., Pani L., Serra G., and Fratta W. Animal models of mania. Adv. Biochem. Psychopharmacol. 49 (1995) 43-66
14. Graybiel A.M., Moratalla R., and Robertson H.A. Amphetamine and cocaine induce drug-specific activation of the c-fos gene in striosome-matrix compartments and limbic subdivisions of the striatum. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 6912-6916
15. Kuzmin A., Madjid N., Terenius L., Ogren S.O., and Bakalkin G. big dynorphin, a prodynorphin-derived peptide produces NMDA receptor-mediated effects on memory, anxiolytic-like and locomotor behavior in mice. Neuropsychopharmacology 31 (2006) 1928-1937
16. Lenox R.H., Gould T.D., and Manji H.K. Endophenotypes in bipolar disorder. Am. J. Med. Genet. 114 (2002) 391-406
17. Lin C.H., Yeh S.H., Leu T.H., Chang W.C., Wang S.T., and Gean P.W. Identification of calcineurin as a key signal in the extinction of fear memory. J. Neurosci. 23 (2003) 1574-1579
18. Linden A.M., Greene S.J., Bergeron M., and Schoepp D.D. Anxiolytic activity of the MGLU2/3 receptor agonist LY354740 on the elevated plus maze is associated with the suppression of stress-induced c-Fos in the hippocampus and increases in c-Fos induction in several other stress-sensitive brain regions. Neuropsychopharmacology 29 (2004) 502-513
19. Machado-Vieira R., Kapczinski F., and Soares J.C. Perspectives for the development of animal models of bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 28 (2004) 209-224
20. Malleret G., Haditsch U., Genoux D., Jones M.W., Bliss T.V., Vanhoose A.M., Weitlauf C., Kandel E.R., Winder D.G., and Mansuy I.M. Inducible and reversible enhancement of learning, memory, and long-term potentiation by genetic inhibition of calcineurin. Cell 104 (2001) 675-686
21. Manji H.K., Gottesman I.I., and Gould T.D. Signal transduction and genes-to-behaviors pathways in psychiatric diseases. Sci. STKE 207 (2003) pe49
22. Mansuy I.M., Mayford M., Jacob B., Kandel E.R., and Bach M.E. Restricted and regulated overexpression reveals calcineurin as a key component in the transition from short-term to long-term memory. Cell 92 (1998) 39-49
23. Mansuy I.M., Winder D.G., Moallem T.M., Osman M., Mayford M., Hawkins R.D., and Kandel E.R. Inducible and reversible gene expression with the rtTA system for the study of memory. Neuron 21 (1998) 257-265
24. Miyakawa T., Leiter L.M., Gerber D.J., Gainetdinov R.R., Sotnikova T.D., Zeng H., Caron M.G., and Tonegawa S. Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 8987-8992
25. Ognibene E., Middei S., Daniele S., Adriani W., Ghirardi O., Caprioli A., and Laviola G. Aspects of spatial memory and behavioral disinhibition in Tg2576 transgenic mice as a model of Alzheimer's disease. Behav. Brain Res. 156 (2005) 225-232
26. Olausson P., Ericson M., Lof E., Engel J.A., and Soderpalm B. Nicotine-induced behavioral disinhibition and ethanol preference correlate after repeated nicotine treatment. Eur. J. Pharmacol. 417 (2001) 117-123
27. Pellow S., and File S.E. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol. Biochem. Behav. 24 (1986) 525-529
28. Ron D., and Jurd R. The "ups and downs" of signaling cascades in addiction. Sci. STKE 2005 309 (2005) re14
29. Roybal K., Theobold D., Graham A., Dinieri J.A., Russo S.J., Krishnan V., Chakravarty S., Peevey J., Oehrlein N., Birnbaum S., Vitaterna M.H., Orsulak P., Takahashi J.S., Nestler E.J., Carlezon Jr. W.A., and McClung C.A. Mania-like behavior induced by disruption of CLOCK. Proc. Natl. Acad. Sci. U. S. A. 10 (2007) 6406-6411
30. Rozeboom A.M., Akil H., and Seasholtz A.F. Mineralocorticoid receptor overexpression in forebrain decreases anxiety-like behavior and alters the stress response in mice. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 4688-4693
31. Shaldubina A., Einat H., Szechtman H., Shimon H., and Belmaker R.H. Preliminary evaluation of oral anticonvulsant treatment in the quinpirole model of bipolar disorder. J. Neural Transm. 109 (2002) 433-440
32. Shepherd J.K., Grewal S.S., Fletcher A., Bill D.J., and Dourish C.T. Behavioural and pharmacological characterisation of the elevated "zero-maze" as an animal model of anxiety. Psychopharmacology (Berl) 116 (1994) 56-64
33. Steiner H., and Gerfen C.R. Cocaine-induced c-fos messenger RNA is inversely related to dynorphin expression in striatum. J. Neurosci. 13 (1993) 5066-5081
34. Svenningsson P., Tzavara E.T., Carruthers R., Rachleff I., Wattler S., Nehls M., McKinzie D.L., Fienberg A.A., Nomikos G.G., and Greengard P. Diverse psychotomimetics act through a common signaling pathway. Science 302 (2003) 1412-1415
35. Svenningsson P., Tzavara E.T., Witkin J.M., Fienberg A.A., Nomikos G.G., and Greengard P. Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 3182-3187
36. Tzavara E.T., Monory K., Hanoune J., and Nomikos G.G. Nicotine withdrawal syndrome: behavioral distress and selective up-regulation of the cyclic AMP-pathway in the amygdala. Eur. J. Neurosci. 16 (2002) 149-153
37. Tzavara E.T., Pouille Y., Defer N., and Hanoune J. Diurnal variation of the adenylyl cyclase type 1 in the rat pineal gland. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 11208-11212
38. Valverde O., Tzavara E., Hanoune J., Roques B.P., and Maldonado R. Protein kinases in the rat nucleus accumbens are involved in the aversive component of opiate withdrawal. Eur. J. Neurosci. 8 (1996) 2671-2678
39. Winder D.G., Mansuy I.M., Osman M., Moallem T.M., and Kandel E.R. Genetic and pharmacological evidence for a novel, intermediate phase of long-term potentiation suppressed by calcineurin. Cell 92 (1998) 25-37
40. White D.A., Kalinichev M., and Holtzman S.G. Locomotor response to novelty as a predictor of reactivity to aversive stimuli in the rat. Brain Res. 1149 (2007) 141-148
41. Xia Z., and Storm D.R. The role of calmodulin as a signal integrator for synaptic plasticity. Nat. Rev., Neurosci. 6 (2005) 267-276
42. Zeng H., Chattarji S., Barbarosie M., Rondi-Reig L., Philpot B.D., Miyakawa T., Bear M.F., and Tonegawa S. Forebrain-specific calcineurin knockout selectively impairs bidirectional synaptic plasticity and working/episodic-like memory. Cell 107 (2001) 617-629
43. Zorner B., Wolfer D.P., Brandis D., Kretz O., Zacher C., Madani R., Grunwald I., Lipp H.P., Klein R., Henn F.A., and Gass P. Forebrain-specific trkB-receptor knockout mice: behaviorally more hyperactive than "depressive". Biol. Psychiatry 54 (2003) 972-982